StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Barclays Downgrades Moderna (MRNA) to Equalweight
February 18, 2025 5:13 AM
Barclays analyst Gena Wang downgraded Moderna (NASDAQ: MRNA) from Overweight to Equalweight with a price target of $45.00 (from $111.00).The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Next Articles
Bernstein SocGen Group Reiterates Market Perform Rating on Moderna (MRNA)
February 17, 2025 9:15 AM
Form 4 Moderna, Inc. For: Feb 12 Filed by: Klinger Shannon Thyme
February 14, 2025 4:16 PM
Form 4 Moderna, Inc. For: Feb 12 Filed by: Hoge Stephen
February 14, 2025 4:13 PM
Form 4 Moderna, Inc. For: Feb 12 Filed by: Bancel Stephane
February 14, 2025 4:07 PM
Moderna (MRNA) PT Lowered to $25 at Wolfe Research
February 14, 2025 2:07 PM
Moderna (MRNA) Misses Q4 EPS by 18c; offers guidance
February 14, 2025 7:10 AM
Moderna norovirus vaccine trial on hold by US FDA over neurological side effect
February 14, 2025 6:34 AM
Form 8-K Moderna, Inc. For: Feb 14
February 14, 2025 6:31 AM
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
February 14, 2025 6:29 AM
Moderna faces revenue pressures as analysts cut estimates ahead of earnings
February 14, 2025 2:00 AM
